Role of toll-like receptor-4 in renal graft ischemia-reperfusion injury

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 8, 2014, Pages

  Zhao, Hailin ^a   Perez, Jessica Santiváñez ^a   Lu, Kaizhi ^b   George, Andrew J T ^c   Ma, Daqing ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Delayed graft function; Ischemia reperfusion injury; Renal graft failure; Renal transplantation; Toll like receptor 4

Indexed keywords

BIGLYCAN; HEAT SHOCK PROTEIN 70; HEPARAN SULFATE; HIGH MOBILITY GROUP BOX CHROMOSOMAL PROTEIN 1; HIGH MOBILITY GROUP PROTEIN; HYALURONIC ACID; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CELL DEATH; DELAYED GRAFT FUNCTION; ENDOTHELIUM CELL; EPITHELIUM CELL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INNATE IMMUNITY; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LEUKOCYTE MIGRATION; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

DELAYED GRAFT FUNCTION; ISCHEMIA-REPERFUSION INJURY; RENAL GRAFT FAILURE; RENAL TRANSPLANTATION; TOLL-LIKE RECEPTOR 4;

ANIMALS; BIGLYCAN; GRAFT REJECTION; HEAT-SHOCK PROTEINS; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; KIDNEY TRANSPLANTATION; KIDNEY TUBULAR NECROSIS, ACUTE; MYELOID DIFFERENTIATION FACTOR 88; POLYMORPHISM, GENETIC; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84900525694     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00469.2013     Document Type: Review

References (98)

1. Ali S, Malik G, Burns A, Robertson H, Kirby JA. Renal transplantation: examination of the regulation of chemokine binding during acute rejection. Transplantation 79: 672-679, 2005.
2. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 72: 1084-1091, 2002.
3. Andrade-Oliveira V, Campos EF, Goncalves-Primo A, Grenzi PC, Medina-Pestana JO, Tedesco-Silva H, Gerbase-DeLima M. TLR4 mRNA levels as tools to estimate risk for early posttransplantation kidney graft dysfunction. Transplantation 94: 589-595, 2012.
4. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25: 187-191, 2000.
5. Atkinson SJ, Hosford MA, Molitoris BA. Mechanism of actin polymerization in cellular ATP depletion. J Biol Chem 279: 5194-5199, 2004.
6. Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291: C1318-C1325, 2006.
7. Ben Mkaddem S, Pedruzzi E, Werts C, Coant N, Bens M, Cluzeaud F, Goujon JM, Ogier-Denis E, Vandewalle A. Heat shock protein gp96 and NAD(P)H oxidase 4 play key roles in Toll-like receptor 4-activated apoptosis during renal ischemia/reperfusion injury. Cell Death Differ 17: 1474-1485, 2010.
8. Bergler T, Hoffmann U, Bergler E, Jung B, Banas MC, Reinhold SW, Kramer BK, Banas B. Toll-like receptor 4 in experimental kidney transplantation: early mediator of endogenous danger signals. Nephron Exp Nephrol 121: e59-e70, 2012.
9. Braudeau C, Ashton-Chess J, Giral M, Dugast E, Louis S, Pallier A, Braud C, Moreau A, Renaudin K, Soulillou JP, Brouard S. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation 86: 130-136, 2008.
10. Campbell MT, Hile KL, Zhang H, Asanuma H, Vanderbrink BA, Rink RR, Meldrum KK. Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. J Surg Res 168: e61-e69, 2011.
11. Chen J, John R, Richardson JA, Shelton JM, Zhou XJ, Wang Y, Wu QQ, Hartono JR, Winterberg PD, Lu CY. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int 79: 288-299, 2011.
12. Chen J, Hartono JR, John R, Bennett M, Zhou XJ, Wang Y, Wu Q, Winterberg PD, Nagami GT, Lu CY. Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int 80: 504-515, 2011.
13. Chen J, Matzuk MM, Zhou XJ, Lu CY. Endothelial pentraxin 3 contributes to murine ischemic acute kidney injury. Kidney Int 82: 1195-1207, 2012.
14. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 128: 170-179, 2004.
15. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 6: 571-578, 2005.
16. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 71: 619-628, 2007.
17. Ducloux D, Deschamps M, Yannaraki M, Ferrand C, Bamoulid J, Saas P, Kazory A, Chalopin JM, Tiberghien P. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 67: 2454-2461, 2005.
18. El-Achkar TM, Wu XR, Rauchman M, McCracken R, Kiefer S, Dagher PC. Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol 295: F534-F544, 2008.
19. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 17: 1391-1401, 2011.
20. Fekete A, Viklicky O, Hubacek JA, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, Heemann U, Reusz G, Szabo AJ. Association between heat shock protein 70s and toll-like receptor polymorphisms with longterm renal allograft survival. Transpl Int 19: 190-196, 2006.
21. Figueroa L, Xiong Y, Song C, Piao W, Vogel SN, Medvedev AE. The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF. J Immunol 188: 4506-4515, 2012.
22. Fineschi S, Goffin L, Rezzonico R, Cozzi F, Dayer JM, Meroni PL, Chizzolini C. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of Toll-like receptor 4. Arthritis Rheum 58: 3913-3923, 2008.
23. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4: 491-496, 2003.
24. Gailit J, Colflesh D, Rabiner I, Simone J, Goligorsky MS. Redistribution and dysfunction of integrins in cultured renal epithelial cells exposed to oxidative stress. Am J Physiol Renal Fluid Electrolyte Physiol 264: F149-F157, 1993.
25. Ganea D, Rodriguez R, Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol (Noisy-le-grand) 49: 127-142, 2003.
26. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 6: 224-235, 2010.
27. Gok MA, Shenton BK, Pelsers M, Whitwood A, Mantle D, Cornell C, Peaston R, Rix D, Jaques BC, Soomro NA, Manas DM, Talbot D. Ischemia-reperfusion injury in cadaveric nonheart beating, cadaveric heart beating and live donor renal transplants. J Urol 175: 641-647, 2006.
28. Gordon EJ, Ladner DP, Caicedo JC, Franklin J. Disparities in kidney transplant outcomes: a review. Semin Nephrol 30: 81-89.
29. Gu J, Sun P, Zhao H, Watts HR, Sanders RD, Terrando N, Xia P, Maze M, Ma D. Dexmedetomidine provides renoprotection against ischemia- reperfusion injury in mice. Crit Care 15: R153, 2011.
30. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012.
31. Hauet T, Eugene M. A new approach in organ preservation: potential role of new polymers. Kidney Int 74: 998-1003, 2008.
32. Hwang YH, Ro H, Choi I, Kim H, Oh KH, Hwang JI, Park MH, Kim S, Yang J, Ahn C. Impact of polymorphisms of TLR4/CD14 and TLR3 on acute rejection in kidney transplantation. Transplantation 88: 699-705, 2009.
33. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 130: 41-50, 2009.
34. Ji H, Zhang Y, Shen XD, Gao F, Huang CY, Abad C, Busuttil RW, Waschek JA, Kupiec-Weglinski JW. Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMPPKA pathway. Hepatology 57: 1225-1237, 2013.
35. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant 21: 1231-1239, 2006.
36. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 168: 5233-5239, 2002.
37. Johnson GB, Brunn GJ, Tang AH, Platt JL. Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol 24: 19-24, 2003.
38. Kim BS, Lim SW, Li C, Kim JS, Sun BK, Ahn KO, Han SW, Kim J, Yang CW. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation 79: 1370-1377, 2005.
39. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 23: 842-852, 2008.
40. Kolanowski ST, Dieker MC, Lissenberg-Thunnissen SN, van Schijndel GM, van Ham SM, Ten Brinke A. TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF. Innate Immun [Epub ahead of print].
41. Kruger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, Lin M, Walsh L, Vella J, Fischereder M, Kramer BK, Colvin RB, Heeger PS, Murphy BT, Schroppel B. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 106: 3390-3395, 2009.
42. Kuboki S, Schuster R, Blanchard J, Pritts TA, Wong HR, Lentsch AB. Role of heat shock protein 70 in hepatic ischemia-reperfusion injury in mice. Am J Physiol Gastrointest Liver Physiol 292: G1141-G1149, 2007.
43. Kwon J, Park J, Lee D, Kim YS, Jeong HJ. Toll-like receptor expression in patients with renal allograft dysfunction. Transplant Proc 40: 3479-3480, 2008.
44. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678-689, 2007.
45. Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 5: 513-519, 2009.
46. Li L, Okusa MD. Blocking the immune response in ischemic acute kidney injury: the role of adenosine 2A agonists. Nat Clin Pract Nephrol 2: 432-444, 2006.
47. Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemiareperfusion injury. Semin Nephrol 30: 268-277, 2010.
48. Li M, Khan AM, Maderdrut JL, Simon EE, Batuman V. The effect of PACAP38 on MyD88-mediated signal transduction in ischemia-/hypoxiainduced acute kidney injury. Am J Nephrol 32: 522-532.
49. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5: 446-458, 2005.
50. Lim SW, Li C, Ahn KO, Kim J, Moon IS, Ahn C, Lee JR, Yang CW. Cyclosporine-induced renal injury induces toll-like receptor and maturation of dendritic cells. Transplantation 80: 691-699, 2005.
51. Liu M, Gu M, Xu D, Lv Q, Zhang W, Wu Y. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant Proc 42: 1539-1544.
52. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7: 684-696, 2011.
53. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
54. Mantell LL, Parrish WR, Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25: 4-11, 2006.
55. Mikhalski D, Wissing KM, Ghisdal L, Broeders N, Touly M, Hoang AD, Loi P, Mboti F, Donckier V, Vereerstraeten P, Abramowicz D. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 85: S3-S9, 2008.
56. +-ATPase from its surface membrane actin cytoskeletal complex during cellular ATP depletion. J Clin Invest 88: 462-469, 1991.
57. Moreira P, Sa H, Figueiredo A, Mota A. Delayed renal graft function: risk factors and impact on the outcome of transplantation. Transplant Proc 43: 100-105.
58. Mutlubas F, Mir S, Berdeli A, Ozkayin N, Sozeri B. Association between Toll-like receptors 4 and 2 gene polymorphisms with chronic allograft nephropathy in Turkish children. Transplant Proc 41: 1589-1593, 2009.
59. Nogueira E, Ozaki KS, Macusso GD, Quarim RF, Camara NO, Pacheco-Silva A. Incidence of donor and recipient Toll-like receptor-4 polymorphisms in kidney transplantation. Transplant Proc 39: 412-414, 2007.
60. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276: 10229-10233, 2001.
61. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7: 353-364, 2007.
62. Palmer SM, Burch LH, Mir S, Smith SR, Kuo PC, Herczyk WF, Reinsmoen NL, Schwartz DA. Donor polymorphisms in Toll-like receptor- 4 influence the development of rejection after renal transplantation. Clin Transplant 20: 30-36, 2006.
63. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 364: 1814-1827, 2004.
64. + T cells retaining CD28. Blood 117: 6542-6551, 2011.
65. Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, van der Poll T, Florquin S, Leemans JC. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol 21: 1299-1308, 2010.
66. Pulskens WP, Teske GJ, Butter LM, Roelofs JJ, van der Poll T, Florquin S, Leemans JC. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS One 3: e3596, 2008.
67. Qin J, Qian Y, Yao J, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 280: 25233-25241, 2005.
68. Requiao-Moura LR, Durao Mde S, Tonato EJ, Matos AC, Ozaki KS, Camara NO, Pacheco-Silva A. Effects of ischemia and reperfusion injury on long-term graft function. Transplant Proc 43: 70-73.
69. Rusai K, Sollinger D, Baumann M, Wagner B, Strobl M, Schmaderer C, Roos M, Kirschning C, Heemann U, Lutz J. Toll-like receptors 2 and 4 in renal ischemia/reperfusion injury. Pediatr Nephrol 25: 853-860.
70. Saemann MD, Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y, Stulnig TM, Akira S, von Gabain A, von Ahsen U, Horl WH, Zlabinger GJ. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest 115: 468-475, 2005.
71. Salahudeen AK. Cold ischemic injury of transplanted kidneys: new insights from experimental studies. Am J Physiol Renal Physiol 287: F181-F187, 2004.
72. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, Malle E, Schaefer RM, Grone HJ. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223-2233, 2005.
73. Snoeijs MG, Vink H, Voesten N, Christiaans MH, Daemen JW, Peppelenbosch AG, Tordoir JH, Peutz-Kootstra CJ, Buurman WA, Schurink GW, van Heurn LW. Acute ischemic injury to the renal microvasculature in human kidney transplantation. Am J Physiol Renal Physiol 299: F1134-F1140, 2010.
74. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 21: 335-376, 2003.
75. Tang Y, Lv B, Wang H, Xiao X, Zuo X. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Int Immunopharmacol 8: 1646-1651, 2008.
76. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 195: 99-111, 2002.
77. Tilney NL, Guttmann RD. Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 64: 945-947, 1997.
78. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 76: 514-519, 2004.
79. Tuuminen R, Nykanen AI, Saharinen P, Gautam P, Keranen MA, Arnaudova R, Rouvinen E, Helin H, Tammi R, Rilla K, Krebs R, Lemstrom KB. Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function. Am J Transplant 13: 2019-2034, 2013.
80. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H, Wagner H. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 276: 31332-31339, 2001.
81. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 277: 15107-15112, 2002.
82. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52: 269-324, 2000.
83. Vaudry D, Pamantung TF, Basille M, Rousselle C, Fournier A, Vaudry H, Beauvillain JC, Gonzalez BJ. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 15: 1451-1460, 2002.
84. Wang S, Schmaderer C, Kiss E, Schmidt C, Bonrouhi M, Porubsky S, Gretz N, Schaefer L, Kirschning CJ, Popovic ZV, Grone HJ. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling. Dis Model Mech 3: 92-103, 2010.
85. Wang S, Villablanca EJ, De Calisto J, Gomes DC, Nguyen DD, Mizoguchi E, Kagan JC, Reinecker HC, Hacohen N, Nagler C, Xavier RJ, Rossi-Bergmann B, Chen YB, Blomhoff R, Snapper SB, Mora JR. MyD88-dependent TLR1/2 signals educate dendritic cells with gut-specific imprinting properties. J Immunol 187: 1412-150, 2011.
86. Wang Z, Gall JM, Bonegio RG, Havasi A, Hunt CR, Sherman MY, Schwartz JH, Borkan SC. Induction of heat shock protein 70 inhibits ischemic renal injury. Kidney Int 79: 861-870, 2011.
87. Wangsiripaisan A, Gengaro PE, Edelstein CL, Schrier RW. Role of polymeric Tamm-Horsfall protein in cast formation: oligosaccharide and tubular fluid ions. Kidney Int 59: 932-940, 2001.
88. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ. TLR4 activation mediates kidney ischemia/ reperfusion injury. J Clin Invest 117: 2847-2859, 2007.
89. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, Chadban SJ. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 21: 1878-1890, 2010.
90. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, Takeda K, Akira S. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420: 324-329, 2002.
91. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, Akira S. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 4: 1144-1150, 2003.
92. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 107: 11942-11947, 2010.
93. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 277: 7059-7065, 2002.
94. Zhang W, Gao L, Qi S, Liu D, Xu D, Peng J, Daloze P, Chen H, Buelow R. Blocking of CD44-hyaluronic acid interaction prolongs rat allograft survival. Transplantation 69: 665-667, 2000.
95. Zhao H, Luo X, Zhou Z, Liu J, Tralau-Stewart C, George AJ, Ma D. Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats. Kidney Int 85: 112-23, 2014.
96. Zhao H, Ning J, Savage S, Kang H, Lu K, Zheng X, George AJ, Ma D. A novel strategy for preserving renal grafts in an ex vivo setting: potential for enhancing the marginal donor pool. FASEB J 27: 4822-33, 2013.
97. Zhao H, Watts HR, Chong M, Huang H, Tralau-Stewart C, Maxwell PH, Maze M, George AJ, Ma D. Xenon treatment protects against cold ischemia associated delayed graft function and prolongs graft survival in rats. Am J Transplant 13: 2006-2018, 2013.
98. Zhao H, Yoshida A, Xiao W, Ologunde R, O'Dea KP, Takata M, Tralau-Stewart C, George AJ, Ma D. Xenon treatment attenuates early renal allograft injury associated with prolonged hypothermic storage in rats. FASEB J 27: 4076-4088, 2013.